Anti-Mouse PD-1 Antibody (29F.1A12), a rat-derived ntibody targeting PD-1, can specifically block the binding of PD-1 to its ligands PD-L1 and PD-L2. Based on this mechanism of action, it is widely applicable to research in cancer and immunology, including studies on the CT26 tumor model and pancreatic cancer research. Its isotype control is Rat IgG2a kappa Isotype Control.

Anti-Mouse PD-1 Antibody (29F.1A12) (10 μg/mL for 7 days), when used in combination with an anti-CTLA-4 antibody, significantly promotes the secretion of the IFN-γ cytokine and upregulates the expression level of Ki-67 in CD8+CTLA-4+PD-1+ tumor-infiltrating lymphocytes derived from CT26 tumors [1].

Anti-Mouse PD-1 Antibody (29F.1A12), administered intraperitoneally at a dose of 200 μg on days 10, 13 and 16, induced tumor regression in CT26/ID8-VEGF tumor-bearing mice when combined with an anti-CTLA-4 antibody [1].
Anti-Mouse PD-1 Antibody (29F.1A12), given intraperitoneally at 100 μg on days 1, 3 and 5 after BRAF inhibitor administration, delayed tumor growth and improved survival rates in BP tumor-bearing mice when used in combination with a BRAF inhibitor [2].
Anti-Mouse PD-1 Antibody (29F.1A12), administered intraperitoneally at 200 μg on days 4, 7 and 10, protected pancreatic cancer-bearing mice against primary pancreatic cancer and hepatic metastasis when combined with a PRIP1 inhibitor [3].

29F.1A12

Mouse

Monoclonal

Unconjugated